基底类双阴性前列腺癌中CDH3作为新型治疗点
bioRxiv : the preprint server for biology
|December 3, 2025
概括
CDH3 (P-cadherin) 是激进的基底类前列腺癌的驱动因素. 针对CDH3的疗法,如抗体-药物合物和CAR T细胞,在治疗这种难以治疗的癌症方面显示出显著的临床前前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 基础性前列腺癌是一种具有攻击性的亚型,缺乏有效的向治疗方法.
- CDH3 (P-cadherin) 被研究为这种癌症的潜在治疗点.
- 了解CDH3的作用对于开发新的治疗策略至关重要.
研究的目的:
- 确定CDH3在基础性前列腺癌中的作用.
- 评估CDH3导向的治疗策略,包括抗体-药物合物 (ADC) 和仿制抗原受体 (CAR) T细胞.
主要方法:
- 基因工程小鼠模型 (GEMMs) 和人类数据集的整合.
- 批量和单细胞转录组分析以检查CDH3表达和信号.
- 在体外和体外使用ADC和CAR T细胞向CDH3.3的功能研究.
主要成果:
- 过高的CDH3表达和非正规的WNT信号在攻击性小鼠前列腺瘤.
- 在人类的基础性前列腺癌亚型中,CDH3的调节显著上升.
- 针对CDH3的ADC和CART细胞在临床前模型中表现出强大的抗瘤活性和瘤回归.
结论:
- CDH3是基底类前列腺癌的关键标志物和功能驱动因素.
- 针对CDH3的疗法 (ADC,CAR T细胞) 显示出强大的临床前疗效.
- 这些发现支持开发针对CDH3的治疗方法来治疗侵袭性前列腺癌.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


